Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
CPhI North America CPhI North America
Not Confirmed
Not Confirmed
20-22 May, 2025
World Vaccine Conferen...World Vaccine Conference
Not Confirmed
Not Confirmed
22-24 April, 2025
Not Confirmed
Not Confirmed
22-25 April, 2025
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
CPhI North America CPhI North America
Industry Trade Show
Not Confirmed
20-22 May, 2025
World Vaccine Conferen...World Vaccine Conference
Industry Trade Show
Not Confirmed
22-24 April, 2025
Industry Trade Show
Not Confirmed
22-25 April, 2025
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/our-unmatched-efficiency-and-track-record-of-faster-dmf-filings-give-our-customers-a-critical-competitive-advantage
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/top-pharma-companies-drugs-in-2024-merck-s-keytruda-maintains-top-spot-as-novo-s-semaglutide-nips-at-its-heels
31 Mar 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/03/31/3052242/0/en/Biora-Therapeutics-Successfully-Completes-Restructuring-Process.html
30 Dec 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/12/30/3002651/0/en/Biora-Therapeutics-Undertakes-Chapter-11-Sale-Process-to-Position-Business-for-Future-Growth.html
14 Nov 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/11/14/2981117/0/en/Biora-Therapeutics-Provides-Corporate-Update-and-Reports-Third-Quarter-2024-Financial-Results.html
07 Nov 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/11/07/2977259/0/en/Biora-Therapeutics-to-Report-Third-Quarter-2024-Financial-Results-and-Provide-Corporate-Update.html
29 Oct 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/10/29/2970740/0/en/Biora-Therapeutics-Announces-3-Million-Registered-Direct-Offering-Priced-At-the-Market-Under-Nasdaq-Rules.html
28 Oct 2024
// #N/A
https://www.globenewswire.com/news-release/2024/10/28/2970033/0/en/Biora-Therapeutics-Shares-Progress-on-Smaller-BioJet-Clinical-Device-with-Largest-Payload-of-any-Ingestible-Injectable-at-the-14th-Annual-PODD-Meeting.html
Details:
The net proceeds will be used to fund the clinical development of its oral biotherapeutics platform, BT-600 (tofacitinib) for the treatment of Ulcerative Colitis.
Lead Product(s): Tofacitinib Citrate
Therapeutic Area: Immunology Brand Name: BT-600
Study Phase: Phase IProduct Type: Other Small Molecule
Sponsor: H.C. Wainwright & Co
Deal Size: $3.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering October 29, 2024
Lead Product(s) : Tofacitinib Citrate
Therapeutic Area : Immunology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : H.C. Wainwright & Co
Deal Size : $3.0 million
Deal Type : Public Offering
Biora Therapeutics Prices $3M Direct Offering Under Nasdaq Rules
Details : The net proceeds will be used to fund the clinical development of its oral biotherapeutics platform, BT-600 (tofacitinib) for the treatment of Ulcerative Colitis.
Product Name : BT-600
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
October 29, 2024
Details:
BT-600 (tofacitinib) is a drug-device combination using the NaviCap™ device to deliver a liquid formulation of tofacitinib to the colon, aimed at treating moderate to severe ulcerative colitis.
Lead Product(s): Tofacitinib Citrate
Therapeutic Area: Immunology Brand Name: BT-600
Study Phase: Phase IProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 01, 2024
Lead Product(s) : Tofacitinib Citrate
Therapeutic Area : Immunology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Biora Therapeutics Announces Initiation of Phase 1 Clinical Study of BT-600
Details : BT-600 (tofacitinib) is a drug-device combination using the NaviCap™ device to deliver a liquid formulation of tofacitinib to the colon, aimed at treating moderate to severe ulcerative colitis.
Product Name : BT-600
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 01, 2024
Details:
BT-600 (tofacitinib) is a drug-device combination program consisting of the orally administered NaviCap™ device which delivers tofacitinib to the colon for treatment of ulcerative colitis.
Lead Product(s): Tofacitinib Citrate
Therapeutic Area: Immunology Brand Name: BT-600
Study Phase: Phase IProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 18, 2024
Lead Product(s) : Tofacitinib Citrate
Therapeutic Area : Immunology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Biora Announces Supplemental Data from Phase 1 Trial of BT-600
Details : BT-600 (tofacitinib) is a drug-device combination program consisting of the orally administered NaviCap™ device which delivers tofacitinib to the colon for treatment of ulcerative colitis.
Product Name : BT-600
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 18, 2024
Details:
BT-600 (tofacitinib) is a drug-device combination using the NaviCap™ device to deliver a liquid formulation of tofacitinib to the colon, aimed at treating moderate to severe ulcerative colitis.
Lead Product(s): Tofacitinib Citrate
Therapeutic Area: Immunology Brand Name: BT-600
Study Phase: Phase IProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 30, 2024
Lead Product(s) : Tofacitinib Citrate
Therapeutic Area : Immunology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Biora Completes Multiple-Ascending Dose Cohorts for BT-600 Clinical Trial
Details : BT-600 (tofacitinib) is a drug-device combination using the NaviCap™ device to deliver a liquid formulation of tofacitinib to the colon, aimed at treating moderate to severe ulcerative colitis.
Product Name : BT-600
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 30, 2024
Details:
BT-600 is a drug device combination containing liquid formulation of tofacitinib (JAK inhibitor). It is being evaluated for the treatment of ulcerative colitis
Lead Product(s): Tofacitinib Citrate
Therapeutic Area: Immunology Brand Name: BT-600
Study Phase: Phase IProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 04, 2024
Lead Product(s) : Tofacitinib Citrate
Therapeutic Area : Immunology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Biora Therapeutics Achieves Positive Interim Results for BT-600 in NaviCa Platform Trial
Details : BT-600 is a drug device combination containing liquid formulation of tofacitinib (JAK inhibitor). It is being evaluated for the treatment of ulcerative colitis
Product Name : BT-600
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 04, 2024
Details:
Biora intends to use the net proceeds from this offering to support its operations, complete its ongoing BT-600 (tofacitinib) clinical trial for the treatment of moderate to severe ulcerative colitis.
Lead Product(s): Tofacitinib Citrate
Therapeutic Area: Immunology Brand Name: BT-600
Study Phase: Phase IProduct Type: Other Small Molecule
Sponsor: H.C. Wainwright & Co
Deal Size: $6.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement March 04, 2024
Lead Product(s) : Tofacitinib Citrate
Therapeutic Area : Immunology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : H.C. Wainwright & Co
Deal Size : $6.0 million
Deal Type : Private Placement
Biora Therapeutics Closes $6 Million Registered Direct Offering Priced At-the-Market
Details : Biora intends to use the net proceeds from this offering to support its operations, complete its ongoing BT-600 (tofacitinib) clinical trial for the treatment of moderate to severe ulcerative colitis.
Product Name : BT-600
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
March 04, 2024
Details:
BT-600 (tofacitinib) is a drug-device combination using the NaviCap™ device to deliver a unique liquid formulation of tofacitinib to the colon, aimed at treating moderate to severe ulcerative colitis.
Lead Product(s): Tofacitinib Citrate
Therapeutic Area: Immunology Brand Name: BT-600
Study Phase: Phase IProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 26, 2024
Lead Product(s) : Tofacitinib Citrate
Therapeutic Area : Immunology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Biora Completes Single-Ascending Dose Cohorts for BT-600 Phase 1 Study
Details : BT-600 (tofacitinib) is a drug-device combination using the NaviCap™ device to deliver a unique liquid formulation of tofacitinib to the colon, aimed at treating moderate to severe ulcerative colitis.
Product Name : BT-600
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 26, 2024
Details:
BT-600 (tofacitinib) is a drug-device combination program consisting of the orally administered NaviCap™ device which delivers tofacitinib to the colon for treatment of ulcerative colitis.
Lead Product(s): Tofacitinib Citrate
Therapeutic Area: Immunology Brand Name: BT-600
Study Phase: Phase IProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 07, 2024
Lead Product(s) : Tofacitinib Citrate
Therapeutic Area : Immunology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Biora Therapeutics Announces Positive Clinical Trial Results for BT-600
Details : BT-600 (tofacitinib) is a drug-device combination program consisting of the orally administered NaviCap™ device which delivers tofacitinib to the colon for treatment of ulcerative colitis.
Product Name : BT-600
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 07, 2024
Details:
Biora intends to complete its clinical trial of BT-600, a drug-device combination delivering tofacitinib to the colon for treating moderate to severe ulcerative colitis.
Lead Product(s): Tofacitinib Citrate
Therapeutic Area: Immunology Brand Name: BT-600
Study Phase: Phase IProduct Type: Other Small Molecule
Sponsor: H.C. Wainwright & Co
Deal Size: $6.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering January 04, 2024
Lead Product(s) : Tofacitinib Citrate
Therapeutic Area : Immunology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : H.C. Wainwright & Co
Deal Size : $6.0 million
Deal Type : Public Offering
Biora Announces $6 Million Direct Offering Priced At-the-Market
Details : Biora intends to complete its clinical trial of BT-600, a drug-device combination delivering tofacitinib to the colon for treating moderate to severe ulcerative colitis.
Product Name : BT-600
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
January 04, 2024
Details:
BT-600 (tofacitinib) is a drug/device combination designed to use Biora’s NaviCap™ ingestible drug delivery device with a proprietary liquid formulation of tofacitinib. It is being evaluated for the treatment of Ulcerative Colitis.
Lead Product(s): Tofacitinib Citrate
Therapeutic Area: Immunology Brand Name: BT-600
Study Phase: IND EnablingProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 29, 2023
Lead Product(s) : Tofacitinib Citrate
Therapeutic Area : Immunology
Highest Development Status : IND Enabling
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : BT-600 (tofacitinib) is a drug/device combination designed to use Biora’s NaviCap™ ingestible drug delivery device with a proprietary liquid formulation of tofacitinib. It is being evaluated for the treatment of Ulcerative Colitis.
Product Name : BT-600
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 29, 2023
ABOUT THIS PAGE